Orgenesis Inc. operates a pioneering decentralized cell processing (DCP) platform aimed at scalable, automated production of advanced cell and gene therapies near patient care sites. Its innovative approach targets the high cost and logistic complexities of traditional centralized manufacturing. However, the company struggles with ongoing losses, a deteriorated balance sheet, and extremely limited liquidity, raising substantial doubt about its ability to continue as a going concern. Revenue growth has been stagnant while operational expenses and losses have expanded significantly. The firm’s future hinges on securing additional capital and successfully commercializing therapies through partnerships and decentralized manufacturing units—both of which remain uncertain.